about
Molecular diagnostics for lassa fever at Irrua specialist teaching hospital, Nigeria: lessons learnt from two years of laboratory operationGenomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreakLassa fever in post-conflict sierra leoneLEF-1 negatively controls interleukin-4 expression through a proximal promoter regulatory elementEbola Virus Epidemiology, Transmission, and Evolution during Seven Months in Sierra LeoneMultiple circulating infections can mimic the early stages of viral hemorrhagic fevers and possible human exposure to filoviruses in Sierra Leone prior to the 2014 outbreakRoots, Not Parachutes: Research Collaborations Combat OutbreaksNavigating the Zika panicThe evolution of Ebola virus: Insights from the 2013–2016 epidemicA laboratory in your pocketSpecific immunosuppression with inducible Foxp3-transduced polyclonal T cellsMost neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunitsMultiple introductions of Zika virus into the United States revealed through genomic epidemiologyEpidemic establishment and cryptic transmission of Zika virus in Brazil and the AmericasMultiplex PCR method for MinION and Illumina sequencing of Zika and other virus genomes directly from clinical samplesLassa hemorrhagic fever in a late term pregnancy from northern Sierra Leone with a positive maternal outcome: case reportGenome sequencing reveals Zika virus diversity and spread in the AmericasGenetic characterization of the Zika virus epidemic in the US Virgin IslandsVirus genomes reveal factors that spread and sustained the Ebola epidemicMultiplex PCR method for MinION and Illumina sequencing of Zika and other virus genomes directly from clinical samples.Zika virus evolution and spread in the Americas.Genomic epidemiology reveals multiple introductions of Zika virus into the United States.Research capacity. Enabling the genomic revolution in Africa.Nomenclature- and database-compatible names for the two Ebola virus variants that emerged in Guinea and the Democratic Republic of the Congo in 2014.Enhanced methods for unbiased deep sequencing of Lassa and Ebola RNA viruses from clinical and biological samples.Evaluation of the potential impact of Ebola virus genomic drift on the efficacy of sequence-based candidate therapeutics.Clinical illness and outcomes in patients with Ebola in Sierra Leone.GB virus C coinfections in west African Ebola patients.Discovery of novel rhabdoviruses in the blood of healthy individuals from West Africa.Alloantigen-enhanced accumulation of CCR5+ 'effector' regulatory T cells in the gravid uterus.Genome-wide scans provide evidence for positive selection of genes implicated in Lassa feverComparative Genomics Reveals Key Gain-of-Function Events in Foxp3 during Regulatory T Cell Evolution.Clinical Sequencing Uncovers Origins and Evolution of Lassa VirusDirect Identification of Hundreds of Expression-Modulating Variants using a Multiplexed Reporter Assay.Foxp3 expression is required for the induction of therapeutic tissue toleranceStructures of Ebola virus GP and sGP in complex with therapeutic antibodies.Ebola Virus Epidemiology and Evolution in Nigeria.An Outbreak of Ebola Virus Disease in the Lassa Fever Zone.High-Definition Medicine.Epidemiology. Emerging disease or diagnosis?
P50
Q21092277-DC532DC1-CA65-42F5-8C9B-82125DBF022BQ23000449-20638BA1-DE79-4554-8EB1-0D79FCED47F4Q24290732-E158FDF5-E5DB-4B90-8446-9B03CAD80D77Q24329083-BBF1D0A3-43B1-4A96-A3B7-1F6B18B6AC93Q24696014-9EECC643-9FB7-4C70-B012-F45F8BB4F363Q24701722-F97B6E1B-96F0-408B-8447-B32779E92FE2Q25197488-14C9D699-FE3D-449C-8281-3A72560DEFD7Q26247567-AF6C6CD4-986B-4910-98D5-E05C2AE46C5FQ27231613-2F641134-F26E-4AE7-9336-985CCB47CBBEQ27276923-D7EC2F08-CC1A-4069-88D5-2F30D5349693Q27276923-F68D1424-24CA-46C2-AE00-0E7C3D072237Q28474036-983193F8-BD7D-4747-B717-4D9CD9E97316Q28602816-12C66F6B-1C3B-4D93-9A41-63F553FEE3FAQ28655823-63285C6B-FC8A-4B6B-8DE4-47A7B4FCB290Q28656347-0999A000-56F0-4785-AFB1-B1255DBA4F1FQ28733570-0DCFF060-7779-452F-B400-B5A0EDBEA697Q28744660-381BBAC9-5C9F-4B7F-8784-4A05D1274D2FQ28803990-41857D15-F8A1-41FA-B50D-D51223E93212Q28956593-35C645B6-116A-4ED0-9619-E4A5110D77A2Q29394299-4DA59D4C-3A40-4F63-A7AE-FA9AF23A6B67Q30145570-AD232931-1AAE-481B-8C6E-86580555F9DBQ30145571-C1C99EE4-7B50-45C8-8764-D5ED3C1EF55EQ30145573-EF94D697-6A30-47C1-8A69-1FBC29FC4DD0Q34068017-76D6007E-CF69-4A45-B576-0C0DDFB0E202Q34580917-9A91EBCE-F221-4FFB-A550-F960A4457923Q34676766-0EBA5ED4-5B5E-4DF2-AC86-127E0EFD63D5Q35038226-2D013036-75C8-4EAD-9E26-016BC4FC7C89Q35053891-494EC338-995C-43BA-9185-1321830D87B7Q35115707-5B320E99-8417-4D3C-BBF7-5DCE5321F51CQ35187816-605587E8-6623-4CD1-9845-933F8A0A018DQ35578769-98812969-6CB5-4075-B493-C7A0C431C6B2Q35701103-02403C6E-4E0C-4E90-AE70-005B09D6220AQ35949449-CCE27260-B055-425B-B7B9-6A7B444792AAQ35957928-86863C0A-0468-422C-8EB9-592BB5340427Q36040300-FCECA1B9-E05C-4DBA-BA22-EE281D4DEF94Q36305999-B235FAE4-FB55-4F4F-807F-43A002E7CD6AQ37213985-E95E95B8-F551-418A-81EA-0380BBD9B1C0Q37310759-15C08AEC-4DFD-4ED6-A4DB-4F5333A466ADQ38378926-40DBC93E-ECF9-429F-B932-F705A66E5D24Q38608277-34D8E6CD-7DD9-4551-93F2-BAF425CA9964
P50
description
Director of Infectious Disease Genomics, Scripps Research Translational Institute
@en
hulumtues
@sq
onderzoeker
@nl
հետազոտող
@hy
name
Kristian Andersen
@fr
Kristian G. Andersen
@en
Kristian G. Andersen
@es
Kristian G. Andersen
@nl
Kristian G. Andersen
@sl
type
label
Kristian Andersen
@fr
Kristian G. Andersen
@en
Kristian G. Andersen
@es
Kristian G. Andersen
@nl
Kristian G. Andersen
@sl
altLabel
Kristian Andersen
@en
prefLabel
Kristian Andersen
@fr
Kristian G. Andersen
@en
Kristian G. Andersen
@es
Kristian G. Andersen
@nl
Kristian G. Andersen
@sl
P1053
D-5006-2009
P106
P108
P1960
O5jeEesAAAAJ
P2002
K_G_Andersen
P21
P31
P3829
P496
0000-0001-6431-5982
P569
2000-01-01T00:00:00Z